Reduced Risk Of Stroke, Further Heart Attack And Death For Patients After A Heart Attack Or Unstable Angina With Oral Rivaroxaban

The findings of the ATLAS ACS-TIMI 46 study are reported in an article Online First and in a future edition of The Lancet, and written by Dr Jessica L Mega, Brigham and Women's Hospital, Boston, MA, USA, and collaborators. They suggest that the intake of the oral anti-clotting drug rivaroxaban in patients after an acute coronary syndrome (such as a heart attack or an unstable angina) reduces the risk of stroke, another heart attack, and death.